Search company, investor...

Predict your next investment

Private Equity
huagaicapital.com

See what CB Insights has to offer

Investments

182

Portfolio Exits

11

Funds

10

About Huagai Capital

Huagai Capital is a private equity investment institution that manages a number of equity investment funds such as medical health funds, TMT funds, cultural funds, and more.

Headquarters Location

China Resources Building, 5th Floor, 505-508 Jianguomen North Street No. 8, Dongcheng District

Beijing, Beijing,

China

+8610-6400-1990

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Huagai Capital News

Altamir : NAV down 1.1% in the third quarter. Further diversification with a second co-investment alongside HG Capital

Nov 8, 2022

. Further diversification with a second co-investment alongside HG Capital 11/08/2022 | 12:00pm EST Message : *Required fields Paris, 8 November 2022 – Net Asset Value per share stood at €35.25 as of 30 September 2022, after distribution of a dividend of €1.13/share on 27 May. Including the dividend, NAV was down 3.8% vs 31 December 2021 (€37.81) and 1.1% vs 30 June 2022 (€35.64). We remind investors that as of 31 March and 30 September Altamir revalues only the listed companies in the portfolio and those whose divestment is announced during the quarter. Apax Partners LLP, however, revalues its entire portfolio. If Altamir had used the new valuations communicated by Apax Partners LLP as of 30 September, the NAV would have been €36.04/share (i.e. an increase of 1.1% over the quarter, vs the unadjusted decrease of 1.1%). 1. PERFORMANCE : Net Asset Value (shareholders' equity, IFRS basis) stood at €1,286.9m (vs €1,301.4m as of 30 June 2022 and €1,380.4m as of 31 December 2021). The change in NAV during the quarter resulted from the following factors:   Carried interest paid The reduction in NAV during the quarter mainly reflected the €5.5m decline in the valuation of the high-yield bond fund invested in emerging markets as well as expenses. The value of the portfolio remained stable overall during the quarter despite a significant decline in market comparables in the Tech and Digital sectors, which principally impacted ThoughtWorks and Kar Global. b) €156.5m invested and committed over nine months – Four new investments in the third quarter A total of €156.5m was invested and committed over the first nine months of the year, including €128.2m in nine new companies, €11.8m via Altaroc Global 2021, €6.3m via the Apax Development, Apax Digital and Apax Digital II funds and €10.4m in follow-on investments. During the third quarter, Altamir invested and committed €60.5m, including: €28.0m invested via the Apax MidMarket X fund to acquire Vitaprotech, the French leader in premium solutions for securing sensitive sites. Vitaprotech offers an integrated set of services built around complementary areas of expertise: access control, perimeter intrusion detection, intelligent monitoring and video-surveillance;  €16.1m invested or committed via the Apax X LP fund in two new companies: €11.5m in Authority Brands, a leader in home service franchising in the United States, with a dozen brands ranging from senior care to pool maintenance to outdoor pest control (the Apax IX LP fund has announced the sale of the company to a consortium of funds headed by Apax X LP and British Columbia Investment Management Corporation; the transaction is expected to be finalised in the 4th quarter of 2022); €4.6m in Pickles Auctions, the principal Australian marketplace for cars, motorcycles, industrial and agricultural equipment and salvage vehicles; €10.3m invested alongside HG Capital in Access Group, a UK leader in professional software for mid-sized companies in the United Kingdom and the Asia-Pacific region; €2.6m invested in Altaroc Global 2021 to finance capital calls from underlying funds; €2.1m invested in Apax Development to finance the acquisition of two new companies. €1.4m invested in Apax Digital and Digital II to finance the acquisition of two new companies. b) €113.5m in divestment proceeds and revenue over nine months – €28.2m in the third quarter Divestment proceeds and revenue over the first nine months of 2022 amounted to €113.5m, of which €29.4m derived from four full divestments and €84.1m from additional revenue. During the third quarter, Altamir announced the full divestment of two companies (not yet finalised as of 30 September): Authority Brands, which was held via the Apax IX LP fund (estimated amount: €21m); Boasso Global (ex-Quality Distribution), which was held via the Apax VIII LP fund (estimated amount: €4.4m). During the quarter, Altamir also received €2.8m in additional revenue, deriving principally from the refinancing of Infogain. 3. CASH AND COMMITMENTS Altamir's net cash position as of 30 September 2022 on a statutory basis was €136.4m (vs €157.3m as of 30 June 2022 and €162.9m as of 31 December 2021). This amount did not include the €26.6m disbursed on behalf of the Altaroc funds, which will be reimbursed at the end of the year. Altamir has lines of credit of €90m, including €60m at the Company level and €30m via the dedicated Astra fund. As of 30 September 2022, maximum outstanding commitments totalled €788.1m (including €193.4m invested or committed but not yet called), which will be invested over the next four years, principally as follows: 2022 allocation: €254.0m in the Apax XI LP fund; 2019 allocation: €508.2m, of which: €306.7m in the Apax MidMarket X fund; €101.2m in the Apax X LP fund; €78.0m in the Altaroc Global 2021, 2022 and 2023 funds; $20.0m in the Apax Digital II fund; €3.8m in Dstny; 2016 allocation: €29.5m, of which: €13.0m in distributions recallable by the Apax IX LP fund; €8.8m in the Apax MidMarket IX fund; €3.7m in distributions recallable by the Apax VIII LP fund. In addition, Altamir is temporarily carrying, on behalf of Altaroc Global 2022, €122m in commitments to the Saturn 3 and Genesis 10 funds, managed by HG Capital, and to IFS. Altamir benefits from an opt-out clause, under which it can adjust the level of its commitment to the Apax MidMarket X fund by €100m every six months. About Altamir Altamir is a listed private equity company (Euronext Paris-B, ticker: LTA) founded in 1995 and with a NAV of ca. €1.3bn. Its objective is to provide shareholders with long-term capital appreciation and regular dividends by investing in a diversified portfolio of private equity investments. Altamir's investment policy is to invest principally via and with the funds managed or advised by Apax Partners SAS and Apax Partners LLP, two leading private equity firms that take majority or lead positions in buyouts and growth capital transactions and seek ambitious value creation objectives. In this way, Altamir provides access to a diversified portfolio of fast-growing companies across Apax's sectors of specialisation (Tech & Telco, Consumer, Healthcare, Services) and in complementary market segments (mid-sized companies in continental Europe and large companies in Europe, North America and key emerging markets). Altamir derives certain tax benefits from its status as a SCR ("Société de Capital Risque"). As such, Altamir is exempt from corporate tax and the company's investors may benefit from tax exemptions, subject to specific holding-period and dividend-reinvestment conditions. For more information: www.altamir.fr

Huagai Capital Investments

182 Investments

Huagai Capital has made 182 investments. Their latest investment was in Carmine Therapeutics as part of their Series A on October 10, 2022.

CBI Logo

Huagai Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/13/2022

Series A

Carmine Therapeutics

Yes

2

9/26/2022

Series C

Yiming Cell

No

6

8/23/2022

Series A

DeepWay

$67M

Yes

4

7/21/2022

Series A

Subscribe to see more

Subscribe to see more

10

7/1/2022

Series A

Subscribe to see more

Subscribe to see more

10

Date

10/13/2022

9/26/2022

8/23/2022

7/21/2022

7/1/2022

Round

Series A

Series C

Series A

Series A

Series A

Company

Carmine Therapeutics

Yiming Cell

DeepWay

Subscribe to see more

Subscribe to see more

Amount

$67M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

6

4

10

10

Huagai Capital Portfolio Exits

11 Portfolio Exits

Huagai Capital has 11 portfolio exits. Their latest portfolio exit was MicuRx Pharmaceuticals on August 05, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/5/2022

IPO

$99M

Public

1

2/9/2022

IPO

$99M

Public

1

11/11/2021

IPO

$99M

Public

3

8/30/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

11/20/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/5/2022

2/9/2022

11/11/2021

8/30/2021

11/20/2020

Exit

IPO

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

3

10

10

Huagai Capital Acquisitions

1 Acquisition

Huagai Capital acquired 1 company. Their latest acquisition was Septeo Group on October 15, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/15/2020

Private Equity

$99M

Acq - Fin

1

Date

10/15/2020

Investment Stage

Private Equity

Companies

Valuation

$99M

Total Funding

Note

Acq - Fin

Sources

1

Huagai Capital Fund History

10 Fund Histories

Huagai Capital has 10 funds, including Huagai Capital Healthcare Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/10/2022

Huagai Capital Healthcare Fund III

$125M

1

12/24/2018

Huagai Medical Phase III

$430M

1

12/22/2016

HG Healthcare Fund II

Diversified Private Equity

Open

$188.93M

1

1/5/2015

HG Healthcare Venture Capital Wenzhou Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

11/6/2014

Beijing HG New Material Capital Fund

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

1/10/2022

12/24/2018

12/22/2016

1/5/2015

11/6/2014

Fund

Huagai Capital Healthcare Fund III

Huagai Medical Phase III

HG Healthcare Fund II

HG Healthcare Venture Capital Wenzhou Fund LP

Beijing HG New Material Capital Fund

Fund Type

Diversified Private Equity

Subscribe to see more

Subscribe to see more

Status

Open

Subscribe to see more

Subscribe to see more

Amount

$125M

$430M

$188.93M

$99M

$99M

Sources

1

1

1

10

10

Huagai Capital Team

5 Team Members

Huagai Capital has 5 team members, including current Founding Partner, Binghui Lu.

Name

Work History

Title

Status

Binghui Lu

Founding Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Binghui Lu

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founding Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.